[C1-inhibitor plasma levels in neonates and mothers during labor].

Cesk Pediatr

Ustav hematologie a krevní transfuze, Praha.

Published: December 1993

The authors investigated C1-inhibitor (C1-INH) plasma levels in blood collected from mothers during delivery: mothers with a normal pregnancy and a group of mothers who displayed during the perinatal period direct or indirect signs of infectious disease. Both groups, as compared with a group of healthy donors, had low C1-INH levels. The neonates were divided into two groups (normal children and children with perinatal risk of infection) with sub-groups of mature full-term neonates (38-41 weeks of gestation) and premature infants (29-36 weeks of gestation). In the group of normal infants the neonates had on average somewhat lower C1-INH levels, as compared with healthy donors, in premature neonates of this group the lowest mean C1-INH level was recorded. In this group the authors observed a correlation between the inhibitor level and the gestation period. The results of C1-INH assessment in the group of neonates with a perinatal risk of infection were different. In premature neonates a higher average C1-INH level was observed than in mature neonates and the relationship between the C1-INH level and the gestation period was a linear negative regression. The postnatal increase of C1-INH levels on the 1st to 5th day was more rapid in premature neonates of both groups.

Download full-text PDF

Source

Publication Analysis

Top Keywords

c1-inh levels
12
premature neonates
12
c1-inh level
12
neonates
9
plasma levels
8
levels neonates
8
c1-inh
8
healthy donors
8
perinatal risk
8
risk infection
8

Similar Publications

Indirect treatment comparison of lanadelumab and a C1-esterase inhibitor in pediatric patients with hereditary angioedema.

J Comp Eff Res

January 2025

ICON plc, Insights, Evidence & Value - Health Economics & Epidemiology, Langen, Germany.

To compare the efficacy and safety of lanadelumab versus other approved long-term prophylaxis (LTP) treatments in patients with pediatric hereditary angioedema (HAE) aged <12 years. A systematic literature review was conducted to identify studies of LTP in patients with HAE aged <12 years. Two studies met the inclusion criteria in an indirect treatment comparison of efficacy and safety data in pediatric HAE patients.

View Article and Find Full Text PDF

Background: Although more than four years have passed since the pandemic began, SARS-CoV-2 continues to be of concern. Therefore, research into the underlying mechanisms that contribute to the development of the disease, especially in more severe forms, remains a priority. Sustained activation of the complement (CS), contact (CAS), and fibrinolytic and kinin-kallikrein systems (KKS) has been shown to play a central role in the pathogenesis of the disease.

View Article and Find Full Text PDF

Background: Angioedema (AE) due to acquired C1-inhibitor deficiency (AAE-C1-INH) is a rare disease associating recurrent edema of mucosa and skin. Several underlying diseases have been reported, mainly lymphoproliferative diseases and monoclonal gammopathy. However, 15 to 20% of patients never exhibit such a hematological condition.

View Article and Find Full Text PDF
Article Synopsis
  • Hereditary Angioedema (HAE) is a rare autosomal dominant disorder characterized by low levels or dysfunctional C1 inhibitor, leading to recurrent episodes of swelling and abdominal pain.
  • A reported case involves a 53-year-old man with a longstanding history of recurrent edema and family history, who showed low levels of plasma proteins but faced treatment challenges despite various therapies, including a trial of Lanadelumab for prophylaxis.
  • The patient's experience highlights issues in managing HAE, revealing an adverse reaction to Lanadelumab that is not commonly documented, emphasizing the need for better-informed treatment strategies.
View Article and Find Full Text PDF

Background Hereditary angioedema (HAE) is a rare disorder in India, and while prevalence data is limited, it is believed that a significant number of individuals may be affected. Due to restricted access to first-line treatments, older therapies like danazol are commonly used despite associated risks in resource-constrained settings. This study aimed to assess the efficacy of danazol as an affordable long-term prophylaxis (LTP) for HAE in a three-generation family.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!